Table 2.

Absolute CVD risk estimates in the largest possible sample (n=3012) and stratified by sex and age group (<60 and ≥60 years of age) for different categories of LDL levels, stratified by use of lipid-lowering medication

			Overall sample		Women		Men
	LDL group	LDL treatment	Events (n)/At risk (n)	Crude CVD event rates (95% CI)*	Events (n)/At risk (n)	Crude CVD event rates (95% CI)*	Events (n)/At risk (n)	Crude CVD event rates (95% CI)*
1	<100 mg/dL	No	62/546	9.0 (6.8 to 11.3)	36/348	8.0 (5.4 to 10.6)	26/198	10.9 (6.7 to 15.1)
2	≥100 to <130 mg/dL	No	164/931	14.0 (11.9 to 16.2)	74/506	11.4 (8.8 to 14.1)	90/425	17.2 (13.7 to 20.8)
3	<130 mg/dL	Yes	52/170	26.7 (19.5 to 34.0)	24/75	26.8 (16.1 to 37.5)	28/95	26.7 (16.8 to 36.5)
4	≥130 mg/dL	No	234/1233	15.3 (13.3 to 17.2)	103/667	11.9 (9.6 to 14.3)	131/566	19.5 (16.2 to 22.9)
5	≥130 mg/dL	Yes	36/132	24.1 (16.2 to 31.9)	18/75	20.4 (10.9 to 29.8)	18/57	29.5 (15.9 to 43.1)

			<60 years of age		≥60 years of age
	LDL group	LDL treatment	Events (n)/At risk (n)	Crude CVD event rates (95% CI)*	Events (n)/At risk (n)	Crude CVD event rates (95% CI)*
1	<100 mg/dL	No	15/359	3.2 (1.6 to 4.8)	47/187	22.2 (15.8 to 28.5)
2	≥100 to <130 mg/dL	No	63/551	8.6 (6.5 to 10.7)	101/380	23.2 (18.6 to 27.7)
3	<130 mg/dL	Yes	15/63	19.3 (9.6 to 29.2)	37/107	31.6 (21.4 to 41.8)
4	≥130 mg/dL	No	104/726	11.0 (8.9 to 13.1)	130/507	22.1 (18.3 to 25.9)
5	≥130 mg/dL	Yes	7/45	11.6 (3.0 to 20.2)	29/87	32.5 (20.7 to 44.3)

*Events per 1000 person-years.

CVD, cardiovascular disease; LDL, low-density lipoprotein.